3 Must-Buy Stocks Before 2025 Ends—Top Analysts Reveal Their Picks
Markets are buzzing—these are the equities smart money won't stop buying.
The Contenders: Who Made the Cut?
No fluff, no filler—just the three names dominating institutional portfolios right now. Spoiler: Wall Street still loves tech, but with a twist.
Why These Stocks? (Besides the Obvious FOMO)
Fundamentals? Check. Growth runway? Double-check. A hedge against whatever fresh chaos 2026 brings? Now we're talking.
The Bottom Line
Analysts’ crystal balls say ‘buy’—but remember, these are the same folks who missed three recessions before lunch. Do your own homework.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
For more ideas, you can explore TipRanks’ Analyst Top Stocks tool, which tracks the latest Buy ratings from top-performing analysts in real time.
Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.
(AVPT) – AvePointprovides cloud data management and security solutions for Microsoft 365 usersToday, DBS analyst Sachin Mittal maintained a Buy rating on the stock with a price target of $21.5 per share. Interestingly, nine out of the eleven Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 61.18%.
(DKNG) – This is a digital sports entertainment and online betting company offering fantasy sports and sportsbook services. Today, Needham analyst Bernie McTernan maintained a Buy rating on the stock with a price target of $52 per share. Interestingly, 15 out of the 16 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 57.60%.
(CRSP) – This is a biotechnology company focused on developing gene-editing therapies. Today, Needham analyst Gil Blum maintained a Buy rating on the stock with a price target of $81 per share. Interestingly, seven out of the nine Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 53.61%.
Who Are the Top Analysts?
TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.
